Overview

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Status:
Terminated
Trial end date:
2018-07-23
Target enrollment:
0
Participant gender:
All
Summary
The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Profil Institut für Stoffwechselforschung GmbH
Treatments:
Liraglutide
Lixisenatide
Criteria
Inclusion Criteria:

- Informed consent obtained before any trial-related activities. Trial-related
activities are any procedures that are carried out as part of the trial, including
activities to determine suitability for the trial.

- Male or female aged 18-65 years (both inclusive)

- T2DM diagnosis

Exclusion Criteria:

- Contraindications (including known or suspected hypersensitivity) to GLP-1 mimetics

- Use of GLP-1 mimetics or DPP-IV inhibitors

- Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%